- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Roberto Pili, MD | Authors
Articles
HDAC/mTOR Inhibitor Combination as Treatment for Prostate Cancer
April 08, 2014
Video
Roberto Pili, MD, professor of oncology, chief, genitourinary section leader, Genitourinary Program, Department of Medicine, Roswell Park Cancer Center, discusses the possibility of using a HDAC/mTOR inhibitor combination as a treatment option for patients with prostate cancer.
The Efficacy of Tasquinimod in Men with mCRPC
March 28, 2014
Video
Roberto Pili, MD, professor of oncology, chief, genitourinary section leader, Genitourinary Program, Department of Medicine, Roswell Park Cancer Center, discusses the efficacy of tasquinimod in men with metastatic castration-resistant prostate cancer